Position:
Associate Professor
Canada Research Chair in Neuroepidemiology and Multiple Sclerosis
Phone:
6048220759
Division:
Neurology
Address:
Faculty of Medicine (Neurology); UBC Hospital rm S178
2211 Wesbrook Mall
Vancouver, British Columbia V6T 2B5
Canada
Vision Statement:

To improve the outcome of people affected with multiple sclerosis (MS) by furthering knowledge into disease progression and factors that modify or predict progression; the long-term goal being improved prognosis and an individualized approach to the treatment of chronic disease.

Research Interests:

Multiple sclerosis; disease progression; risk factors; drug treatment for MS (effectiveness and adverse events); sunlight/vitamin D; pregnancy; gut microbiome

Research Sumary:

Epidemiology in Multiple Sclerosis program

Multiple Sclerosis (MS) is a degenerative disease of the brain and spinal cord. Every day, 3 more Canadians are diagnosed with this progressive disorder with no cure. My research goals are to investigate possible underlying factors driving disease progression – from genes to the environment. Whether current MS drugs have any long-term beneficial or even harmful effects will also be examined. A core component of this program will focus on bringing together, for the first time, multiple large health databases created for over two decades by physicians and pharmacists. Ultimately, we aim to improve the health, treatment options and outcome for people with MS.

Personal:

Hiking, cycling, running, swimming, backcountry snowboarding, snowshoeing

Education:
BPharmHons (Bath, UK)
PhD (Cardiff, UK)
Recent Publications:
Awards & Recognition:
  • July 2011-2015 Canada Research Chair program
  • July 2007-2013 Michael Smith Foundation for Health Research Scholar
  • July 2004-2013 Multiple Sclerosis Society of Canada. Don Paty Career Development Award
  • Winner of the 2008 Stephen C. Reingold Award for highest merit-ranked project
  • Awarded by the US National MS Society for the grant proposal titled:‘The BeAMS Study, Long-term Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis’
  • Winner of the 2008 European Charcot Foundation’s Young Investigators Award for Multiple Sclerosis Research
  • US National MS Society [P.I: Tremlett; 2014-2017;‘Prodromal Multiple Sclerosis: The PrOMS Study’]
  • US National MS Society [P.I.:Tremlett; 2013-2016.‘Do the beta-interferons prolong life in people with multiple sclerosis?’]
  • Association pour la Recherche sur la Sclérose en Plaques (ARSEP). [P.I.:Tremlett; 2013-2014; ‘Impact of beta-interferons on survival in patients with multiple sclerosis’]
  • US National MS Society [Co-P.I: Tremlett/ Evans; 2012-2015;‘Adherence to Immunomodulators in Multiple Sclerosis: Prevalence and Clinical Impact (The AIMS Study) ’]
  • Canadian Institutes of Health Research (CIHR) [P.I: Tremlett; 2012-2015; The Children of Multiple Sclerosis: Impact of chronic disease in parents on early childhood development (‘Children of MS’)’]

Please visit group website athttp://epims.med.ubc.ca/